CSL Limited shares were trading around A$176 on 22 December 2025, modestly higher on the session but still nursing a steep 2025 decline that has kept the biotech heavyweight under intense investor scrutiny heading into 2026. [1]
The story around CSL stock (ASX:CSL) right now is a tug-of-war: ongoing confidence in the company’s global plasma and specialty therapies franchise versus uncertainty around its vaccine unit Seqirus, shifting guidance, and the execution risk of a major strategic reset. At the same time, CSL’s on‑market buyback has been a steady presence in daily announcements, offering a tangible signal of capital management even as sentiment remains mixed. [2]
